Showing 1 posts of 1 posts found.
Esperion’s ATP Citrase Lyase (ACL) inhibitor Nexletol (bempedoic acid) has secured approval from the FDA, it has emerged. It is …
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
Functional lung imaging offers new possibilities for respiratory care
Five Facts about cardiovascular disease
Data integrity: the keystone for AI adoption, patient safety and organisational reputation
Artificial hearts: a century of innovation